BNP Paribas Financial Markets
SYRS

BNP Paribas Financial Markets’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

BNP Paribas Financial Markets’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-502
Closed -$3.23K – 4722
2022
Q3 		$3.23K Sell
502
-2,959
-85% -$24K ﹤0.01% 4294
2022
Q2 		$33.3K Buy
3,461
+2,921
+541% +$27.3K ﹤0.01% 3642
2022
Q1 		$6.43K Sell
540
-735
-58% -$13.1K ﹤0.01% 3840
2021
Q4 		$41.6K Buy
1,275
+205
+19% +$8.3K ﹤0.01% 3769
2021
Q3 		$47.8K Buy
1,070
+855
+398% +$41.7K ﹤0.01% 3528
2021
Q2 		$11.7K Sell
215
-401
-65% -$23.7K ﹤0.01% 3686
2021
Q1 		$46K Sell
616
-290
-32% -$30.1K ﹤0.01% 3630
2020
Q4 		$98.3K Sell
906
-111
-11% -$10.1K ﹤0.01% 3222
2020
Q3 		$89.9K Buy
1,017
+704
+225% +$80K ﹤0.01% 3176
2020
Q2 		$33.3K Sell
313
-756
-71% -$67.9K ﹤0.01% 3197
2020
Q1 		$63.4K Buy
1,069
+668
+167% +$45.3K ﹤0.01% 3434
2019
Q4 		$27.7K Sell
401
-48
-11% -$2.91K ﹤0.01% 3908
2019
Q3 		$46.6K Buy
449
+169
+60% +$16K ﹤0.01% 3514
2019
Q2 		$25.9K Sell
280
-246
-47% -$17.1K ﹤0.01% 3802
2019
Q1 		$48.1K Buy
+526
New +$36.6K ﹤0.01% 3514
2018
Q4 		– Sell
-73
Closed -$8.66K – 4448
2018
Q3 		$8.66K Hold
73
– – ﹤0.01% 3805
2018
Q2 		$7.42K Sell
73
-223
-75% -$27.6K ﹤0.01% 3920
2018
Q1 		$38.5K Buy
296
+30
+11% +$3.28K ﹤0.01% 3681
2017
Q4 		$25.9K Buy
266
+134
+102% +$18K ﹤0.01% 3914
2017
Q3 		$19.4K Sell
132
-2
-1% -$376 ﹤0.01% 3608
2017
Q2 		$21.5K Buy
134
+124
+1,240% +$19.5K ﹤0.01% 3619
2017
Q1 		$1.59K Sell
10
-2
-17% -$244 ﹤0.01% 3599
2016
Q4 		$1.46K Sell
12
-5
-29% -$701 ﹤0.01% 3978
2016
Q3 		$2.3K Buy
+17
New +$2.16K ﹤0.01% 3451

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

BNP Paribas Financial Markets's SYRS Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2022, closing a stake of 502 shares — an estimated $3.23K sold.

BNP Paribas Financial Markets first reported a position in SYRS in Q3 2016 and held it in 24 quarters. The position peaked at $98.3K in Q4 2020. 57 funds tracked by Wall St. Rank hold SYRS as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 502 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $3.23K.
  • BNP Paribas Financial Markets first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 24 quarters.
  • BNP Paribas Financial Markets's Syros Pharmaceuticals, Inc. Common Stock position peaked at $98.3K in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.